Eukaryotes rely on mitochondria to produce ATP efficiently, yet this same organelle is the major source of reactive oxygen species (ROS), an endogenous toxin. Mitochondria! dysfunction has been associated with many disorders including type 2 diabetes, obesity and neurodegenerative diseases. Recent work, including much that was funded previously by this grant, has shown that the PGC-1 transcriptional coactivators link mitochondrial function to the external and extracellular environment in many tissues. This new grant proposes experiments that probe the role of PGC-1 a in normal physiology and in a number of diseases involving mitochondrial dysfunction.
Our first Aim will determine the role PGC-1 a in the development of diabetes and obesity in mice, using a muscle-specific KO we have made. Mice will be studied in the basal state and under challenges of high-fat feeding and aging. Glucose homeostasis will be measured with glucose tolerance tests and hyperinsulinemic-euglycemic clamps. We will also study muscle fiber-types and running performance in the presence and absence of PGC-1 a.
Our second Aim will be focused on the collaboration in vitro and in vivo between AMP kinase and PGC-1 a. Our new data indicates that AMPK directly phosphorylates PGC-1 a in vitro and in cells, and requires PGC-1 a to modulate certain programs of gene expression. In our third Aim, we have recently found that PGC-1 a has a powerful ability to suppress the formation of ROS, as it activates mitochondrial respiration. Indeed the ability of ROS to induce a ROS detoxification program is dependent on PGC-1 a and PGC-1 p. We will determine the key molecular events that allow ROS to induce PGC-1 a and, conversely, attempt to understand the transcription factors on which PGC-1 a docks to turn on the ROS detoxification program. We will also attempt to create strains of mice with a mutant PGC-1 a gene which can still regulate OXPHOS but not ROS, and study effects in metabolic disease. These studies should provide new opportunities to modulate oxidative metabolism in ways that allow for new approaches to some important human diseases.
|Kim, Hyeonwoo; Wrann, Christiane D; Jedrychowski, Mark et al. (2018) Irisin Mediates Effects on Bone and Fat via ?V Integrin Receptors. Cell 175:1756-1768.e17|
|Sylow, Lykke; Long, Jonathan Z; Lokurkar, Isha A et al. (2016) The Cancer Drug Dasatinib Increases PGC-1? in Adipose Tissue but Has Adverse Effects on Glucose Tolerance in Obese Mice. Endocrinology 157:4184-4191|
|Long, Jonathan Z; Svensson, Katrin J; Bateman, Leslie A et al. (2016) The Secreted Enzyme PM20D1 Regulates Lipidated Amino Acid Uncouplers of Mitochondria. Cell 166:424-435|
|Liu, Xiaojun; Xiao, Junjie; Zhu, Han et al. (2015) miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab 21:584-95|
|Jedrychowski, Mark P; Wrann, Christiane D; Paulo, Joao A et al. (2015) Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry. Cell Metab 22:734-740|
|Kong, Xingxing; Banks, Alexander; Liu, Tiemin et al. (2014) IRF4 is a key thermogenic transcriptional partner of PGC-1?. Cell 158:69-83|
|Wu, Jun; Spiegelman, Bruce M (2014) Irisin ERKs the fat. Diabetes 63:381-3|
|Wrann, Christiane D; White, James P; Salogiannnis, John et al. (2013) Exercise induces hippocampal BDNF through a PGC-1?/FNDC5 pathway. Cell Metab 18:649-59|
|Kleiner, Sandra; Mepani, Rina J; Laznik, Dina et al. (2012) Development of insulin resistance in mice lacking PGC-1? in adipose tissues. Proc Natl Acad Sci U S A 109:9635-40|
|Boström, Pontus; Wu, Jun; Jedrychowski, Mark P et al. (2012) A PGC1-?-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463-8|
Showing the most recent 10 out of 27 publications